Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Earnings

Immunome's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 2, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

–

EPS, Q3 FY2026

-$0.76

Latest guidance

None

No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Immunome's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 2, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 9, 2026after the close	–	–	-$0.76	Release
Q1 FY2026ended Mar 31, 2026	May 12, 2026after the close	–	–	–	Release
Q4 FY2025ended Dec 31, 2025	Mar 3, 2026after the close	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 6, 2025after the close	–	–	–	Release
Q2 FY2025ended Jun 30, 2025	Aug 6, 2025after the close	–	–	–	Release
Q1 FY2025ended Mar 31, 2025	May 12, 2025after the close	–	–	–	Release
Q4 FY2024ended Dec 31, 2024	Mar 19, 2025after the close	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 13, 2024after the close	–	–	–	Release
Q2 FY2024ended Jun 30, 2024	Aug 12, 2024after the close	$2.36M	-45.0%	-$0.60	Release
Q1 FY2024ended Mar 31, 2024	May 14, 2024before the open	$1.03M	-57.1%	-$2.51	Release
Q4 FY2023ended Dec 31, 2023	Mar 28, 2024after the close	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 9, 2023after the close	$4.00M	–	-$0.36	Release
Q2 FY2023ended Jun 30, 2023	Aug 9, 2023before the open	$4.30M	–	-$0.46	Release
Q1 FY2023ended Mar 31, 2023	May 5, 2023before the open	$2.40M	–	-$0.35	Release
Q4 FY2022ended Dec 31, 2022	Mar 16, 2023before the open	–	–	-$0.64	Release
Q3 FY2022ended Sep 30, 2022	Nov 14, 2022before the open	–	–	-$0.75	Release
Q2 FY2022ended Jun 30, 2022	Aug 5, 2022before the open	–	–	-$0.74	Release
Q1 FY2022ended Mar 31, 2022	May 12, 2022before the open	–	–	-$0.96	Release
Q4 FY2021ended Dec 31, 2021	Mar 28, 2022before the open	–	–	–	Release
Q1 FY2021ended Mar 31, 2021	May 12, 2021before the open	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Mar 25, 2021after the close	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Nov 17, 2020after the close	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Immunome has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Immunome puts a forecast in an earnings release, it is listed here with the exact sentence.